Amarin Announces Phase 3 ANCHOR and MARINE Trial Data to be Presented in November at the American Heart Association's Scientific Sessions

Amarin Corporation plc AMRN today announced that data from each of its two pivotal Phase 3 studies, the ANCHOR trial and the MARINE trial, will be presented at the American Heart Association's Scientific Sessions 2011 in Orlando, Fla. The presentation of the ANCHOR trial results will be the first presentation of data from this trial at a scientific session. The presentation of MARINE trial results will include data that has not been previously presented. The ANCHOR trial results will be presented in an abstract by Christie M. Ballantyne, M.D., Methodist DeBakey Heart and Vascular Center, Houston, and principal investigator of the ANCHOR trial.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsFDAHealth CarePharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!